Clinical Trial Update: PS-341 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating PS-341 (bortezomib) in patients with metastatic kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: University of Chicago | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED